This final approval was to be expected

Sanofi-Aventis directors are said to be celebrating after the weight loss drug Acomplia was given the full approval for cost effectiveness from the National Institute of Clinical Excellence.  This organisation known as NICE for short advises the National Health Service in the United Kingdom whether drugs represent good value for money. This final approval was to be expected after officials from NICE started to release positive reports about the Acomplia weight loss drug in March.

Despite the fact that Acomplia has performed extremely well in clinical testing and has showed to clearly have a positive effect on weight loss when compared to patients who used placebo medication it has not been approved in the United States of America. Sanofi Aventis have also suffered setbacks in Germany where despite the drug having full approval it cannot be given to overweight or obese individuals on private health insurance plans.

The fact that the National Institute of Clinical Excellence in the United Kingdom has now given the Acomplia weight loss drug such good backing may put weight on the Food & Drug Administration in America as well as private health regulators in Germany to give the green light for approval more quickly.

The wording of the NICE approval recommended using the Acomplia weight loss drug along with a sensible diet and exercise. It also noted that this drug would be especially beneficial for those people who had used the weight loss drugs Xenical and Reductil but who had not experienced good results. The official figures from Sanofi Aventis show that sales of the Acomplia weight loss drug amounted to £62 million in 2007 and this figure looks like it is set to grow significantly in 2008.

The weight loss drug Acomplia works differently from any other weight loss medication in that it acts on receptors in the brain that control the desire to eat. It has shown to consistently be an extremely effective appetite suppressant and is available only with a prescription.